This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
The authors made reference to nine primary studies from which effectiveness data were retrieved.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The general rate of recurrence for patients with genital herpes and who were compliant with the acyclovir regime was estimated to be 3%. For patients never treated with acyclovir the recurrence rate was assumed to be 20%. Caesarean section for all the groups was assumed to be 23% in the absence of HSV lesions and 85% with recurrence of HSV at delivery.
Methods used to derive estimates of effectiveness
Authors' assumptions were based on preliminary results from interim analysis of an ongoing study evaluating the efficacy of acyclovir suppression in the last several weeks of pregnancy.
Estimates of effectiveness and key assumptions
The estimated recurrence rate for those not compliant with acyclovir treatment was 30%. The authors assumed that 1% of the infants delivered vaginally in the presence of a lesion would receive acyclovir prophylaxis in the nursery. In the case of non-compliant mothers and those never treated with acyclovir, it was assumed that 2% of the neonates delivered abdominally and 12% of the infants delivered vaginally would be treated prophylactically. Frequency of endometriosis was estimated to be 3% after vaginal deliveries and 20% after Caesarean deliveries.
